Plectranthus amboinicus Extract Modulates Immune Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as psoriasis, atopic dermatitis, and inflammatory bowel disease are inadequate in effectively suppressing immune responses and alleviating symptoms, as they often rely on immunosuppressive drugs with significant side effects and do not address the underlying immune activation pathways.
Innovation Solution
A pharmaceutical composition comprising Plectranthus amboinicus (PA) extract, optionally combined with Centella asiatica (CA) extract, which includes salvigenin, cirsimaritin, rosmarinic acid, and carvacrol, is administered to inhibit immune responses by suppressing CD86 and CD80 expression, altering macrophage subtypes, and modulating immune activation pathways, thereby alleviating psoriatic symptoms and enhancing skin barrier functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive drugs are used to treat autoimmune diseases, then immune responses are suppressed, but significant side effects occur
Solution Approach 1:
The patent extracts specific active compounds (salvigenin, cirsimaritin, rosmarinic acid, carvacrol) from natural plant sources (Plectranthus amboinicus and Centella asiatica) to create a targeted immunosuppressive composition. This extraction approach isolates the beneficial immune-modulating components while eliminating the harmful side effects associated with conventional broad-spectrum immunosuppressive drugs
Solution Approach 2:
The patent uses natural plant extracts as intermediary substances that mediate immune suppression through specific pathways (suppressing CD86 and CD80 expression, altering macrophage subtypes) rather than directly suppressing the entire immune system. These natural compounds act as intermediaries that selectively modulate immune responses while preserving overall immune function
2Ease of operation
If conventional treatments are used for autoimmune diseases, then some symptoms are alleviated, but underlying immune activation pathways are not addressed
Solution Approach 1:
The patent takes preliminary action by targeting the root cause of autoimmune diseases (immune activation pathways) before symptoms fully develop or worsen. The composition proactively suppresses immune activation pathways including IL-17 and IL-23-mediated pathways, preventing disease progression rather than merely treating symptoms after they manifest
Solution Approach 2:
The patent employs natural plant compounds as intermediaries that specifically target and modulate immune activation pathways (IL-17, IL-23, AhR signaling) at the molecular level. These intermediaries act upstream in the disease pathway to address the fundamental immune dysregulation that drives autoimmune diseases, rather than merely treating downstream symptoms
Data Source
AI summary
A method for inhibiting immune responses, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising salvigenin, and optionally cirsimaritin, rosmarinic acid, carvacrol, or a combination thereof.